FGF23 and left ventricular hypertrophy: Recent clinical and observational data suggest that FGF23, a bone-derived hormone that regulates mineral metabolism, is linked to cardiovascular mortality as well as subclinical indices of cardiovascular pathology such as left ventricular hypertrophy, vascular calcification and endothelial dysfunction [2], [3], [4], [5], [6], [7].